Sanofi (DE:SNW)
XETRA:SNW
Earnings Data
Report Date
Apr 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.78Last Year’s EPS
1.38Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong financial and commercial execution in 2025, with robust top-line growth, margin expansion, cash generation, multiple high-impact product launches, and extensive pipeline progress and regulatory approvals. Notable challenges include a Phase III failure (tolebrutinib for PPMS), a safety signal (single Kaposi sarcoma case) requiring monitoring, reductions in Regeneron R&D reimbursement with medium-term BOI implications, and uncertainty in the vaccine market driven by recent U.S. schedule changes. On balance, the company’s positive financial results, successful launches, active BD/investment strategy, and constructive pipeline readouts outweigh the material but manageable challenges.Company Guidance
Strong Top-Line and Q4 Performance
Net sales of EUR 43.6 billion for full year 2025, up 9.9% at constant exchange rates; Q4 sales EUR 11.3 billion, up 13.3% year-over-year.
High EPS and Margin Expansion
Business EPS grew robustly (Q4 business EPS growth cited at 26.7%); full year business EPS excluding buybacks +12.2% and including share buybacks +15%. Business gross margin expanded by 1.8 percentage points to 77.5%; business operating income increased 11.9% with BOI margin of 27.8%.
Strong Cash Generation and Balance Sheet
Free cash flow of EUR 8.1 billion (18.5% of sales) in 2025 with target to sustainably reach at least 20% of net sales in the medium term. Net debt ~EUR 11 billion with a conservative 0.8x net debt-to-EBITDA and AA rating maintained.
Successful New Product Launches and Commercial Momentum
New launches reached EUR 5.7 billion in sales; newly launched medicines and vaccines grew 34% in 2025. ALTUVIIIO achieved blockbuster status with EUR 1.2 billion full year sales. Beyfortus delivered EUR 1.8 billion (up 9.5%) and Dupixent reached EUR 15.7 billion annual sales (quarterly EUR 4.2 billion), with >30% patient growth year-over-year across indications.
Pipeline and Regulatory Delivery
2025 milestones included 12 Phase III readouts, 15 Phase II readouts, 10 new molecules added to Phase I (including 3 gene therapies), 20 regulatory approvals and 22 acceptances. Three new medicines/vaccines approved in 2025: Qfitlia (hemophilia RNAi), Wayrilz (BTK inhibitor for ITP), and Nuvaxovid (recombinant COVID-19 vaccine).
Notable Phase III Wins and Development Programs
Positive Phase III results across most of the amlitelimab atopic dermatitis program and Dupixent met primary endpoint in AFRS; SARCLISA subcutaneous formulation success; multiple late-stage readouts expected in 2026–2027 (amlitelimab remaining trials, lunsekimig, venglustat).
Strategic M&A and Capital Allocation
Completed Opella transaction and deployed EUR 10.4 billion into business development and M&A (including Blueprint, Vicebio, Dren Bio DR-0201, Vigil). Completed EUR 5 billion share buyback program and proposed/announced further BD (proposed Dynavax acquisition for HEPLISAV‑B and shingles candidate); dividend increased +5% to EUR 4.12 (31st consecutive year).
Operational and Sustainability Initiatives
Inventory optimized (reduced by nearly 30 days), OpEx as % of sales reduced to 39.9%, continued investment in U.S. manufacturing capacity, and co-developed PAS 2090 (global standard for measuring/reducing environmental impact of medicines and vaccines).
DE:SNW Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:SNW Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | €77.75 | €77.11 | -0.82% |
Oct 24, 2025 | €86.45 | €88.87 | +2.80% |
Jul 31, 2025 | €85.54 | €79.19 | -7.42% |
Apr 24, 2025 | €89.45 | €89.38 | -0.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Sanofi (DE:SNW) report earnings?
Sanofi (DE:SNW) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
What is Sanofi (DE:SNW) earnings time?
Sanofi (DE:SNW) earnings time is at Apr 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sanofi stock?
The P/E ratio of Sanofi is N/A.
What is DE:SNW EPS forecast?
DE:SNW EPS forecast for the fiscal quarter 2026 (Q1) is 1.78.